Form D · Biotechnology
Aptimmune Biologics, Inc.
Champaign, IL · CIK 0001648213
Offering snapshot reported Jul 11, 2017 · SEC filing
- Reported sold
- $2.2M Offering amount: $7M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $80K Reported outside-investor minimum
- First sale
- Jun 30, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 11, 2017 | Initial | $2,200,000 | No comparison | 3 | SEC filing |
| Mar 24, 2016 | Amendment | $2,420,000 | $1,285,000vs Jul 16, 2015 | 8 | SEC filing |
| Jul 16, 2015 | Initial | $1,135,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-290386
Source: Form D, filed Jul 11, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gary Durack | Director |
| Robert Easter | Director |
| Aaron Gilbertie | Director, Executive |
| Paul Olivo | Director |
| Federico Zuckermann | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
60 Hazelwood Drive
Champaign, IL, 61820
Champaign, IL, 61820